Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

11.33 +0.34 (+3.09%)
Official Closing Price Updated: 7:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,695,740
Open 10.99
Bid (Size) 11.36 (2)
Ask (Size) 11.50 (2)
Prev. Close 10.99
Today's Range 10.92 - 11.51
52wk Range 10.84 - 32.43
Shares Outstanding N/A
Dividend Yield 9.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unleashing Growth Potential: Johnson & Johnson Surpasses Expectations with Strong Performance and Increasing Profits
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga

Performance

YTD
-59.64%
-59.64%
1 Month
-9.79%
-9.79%
3 Month
-42.86%
-42.86%
6 Month
-45.84%
-45.84%
1 Year
-56.67%
-56.67%

More News

Read More
Analyst Expectations for Organon's Future
Via Benzinga
Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?
Via The Motley Fool
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Organon: Dividend Insights
Via Benzinga
Analyst Ratings for Organon
Via Benzinga
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
Via Benzinga
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
From Samsung Bioepis
Via GlobeNewswire
Organon Reports Results for the Third Quarter Ended September 30, 2023
From Organon & Co.
Via Business Wire
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
From Organon & Co.
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
From Organon & Co.
Via Business Wire
Lululemon Athletica Races to New High with S&P 500 Entry
Via MarketBeat
Topics Stocks
Exposures US Equities
Lululemon Athletica To Join S&P 500 Index; LULU Stock Flashes Buy Signal
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
From Organon & Co.
Via Business Wire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2023
Via Benzinga
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
From Organon & Co.
Via Business Wire
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Via The Motley Fool
Stock Analysis: Organon & Co.
Via Talk Markets
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
From Organon & Co.
Via Business Wire
3 Undervalued Healthcare Stocks In 2023
Via Talk Markets
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.